MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of "Buy" by Analysts

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has been assigned an average rating of "Buy" from the eight ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $80.50.

MLTX has been the topic of several research reports. Royal Bank of Canada began coverage on MoonLake Immunotherapeutics in a research note on Tuesday, March 18th. They set an "outperform" rating and a $67.00 price target on the stock. Needham & Company LLC upped their target price on MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. The Goldman Sachs Group lowered their price target on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. Finally, HC Wainwright reissued a "buy" rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a research report on Thursday, February 27th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Deutsche Bank AG raised its stake in shares of MoonLake Immunotherapeutics by 59.8% in the fourth quarter. Deutsche Bank AG now owns 903 shares of the company's stock worth $49,000 after acquiring an additional 338 shares during the last quarter. Birchview Capital LP bought a new position in MoonLake Immunotherapeutics in the 4th quarter worth approximately $217,000. KLP Kapitalforvaltning AS acquired a new position in MoonLake Immunotherapeutics during the 4th quarter worth $244,000. PEAK6 LLC bought a new position in MoonLake Immunotherapeutics in the 4th quarter valued at $271,000. Finally, Mariner LLC acquired a new stake in shares of MoonLake Immunotherapeutics in the 4th quarter valued at $272,000. 93.85% of the stock is owned by institutional investors.

MoonLake Immunotherapeutics Trading Down 1.1 %

NASDAQ:MLTX traded down $0.42 during mid-day trading on Tuesday, hitting $39.03. 133,402 shares of the company's stock traded hands, compared to its average volume of 344,221. The firm has a 50 day moving average of $38.73 and a two-hundred day moving average of $45.67. The firm has a market capitalization of $2.50 billion, a price-to-earnings ratio of -30.37 and a beta of 1.32. MoonLake Immunotherapeutics has a 12 month low of $31.42 and a 12 month high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.09). As a group, equities research analysts expect that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.